Physical and chemical stability of ceftaroline in an elastomeric infusion device. Issue Volume 25:Issue e2(2018) (24th July 2017)

• Record Type: Journal Article
• Authors: Al Madfai, Farah; Zaidi, Syed Tabish R; Ming, Long Chiau; Wanandy, Troy; Patel, Rahul P
• Is Part Of: European journal of hospital pharmacy. Volume 25:Issue e2(2018)
• Page Start: e115
• Page End: e119
• Publication Date: 2017-07-24
• Subjects: ceftaroline -- antibiotics -- elastomeric devices -- continuous infusion -- stability -- multiple bacterial drug resistance; Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2017-001221
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Severe infections such as endocarditis and osteomyelitis require long-term treatment with parenteral antibiotics and hence prolonged hospitalisation. Continuous infusion of ceftaroline through elastomeric devices can facilitate early hospital discharge by managing parenteral antibiotics in patient's home. Therefore, the purpose of this study was to investigate the stability of ceftaroline in a commonly used elastomeric device. Method: A total of 24 elastomeric devices were prepared, and six elastomeric devices containing 6mg/mL of ceftaroline (three in each type of diluents) were stored at one of the following conditions: 4°C for 6 days, 25°C for 24hours, 30°C for 24hours or 35°C for 24hours. An aliquot was withdrawn before storage and at different time points. Chemical stability was measured using a stability indicating high-performance liquid chromatography, and physical stability was assessed as change in pH, colour and particle content. Results: Ceftaroline, when admixed with both diluents, was stable for 144, 24 and 12hours at 4°C, 25°C and 30°C, respectively. At 35°C, ceftaroline admixed with normal saline (NS) and glucose 5% was stable for 12hours and for 6hours, respectively. No evidence of particle formation, colour change or pH change was observed throughout the study period. Conclusions: Our findings support 12 or 24hours continuous elastomeric infusion of ceftaroline-NS admixture, and bulk preparation of elastomeric pumps containing ceftaroline solution in advance. This would facilitate early hospital discharge of patients eligible for the elastomeric-based home therapy and avoid the need for patient's caregivers travelling to the hospital on a daily basis.